Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SALT LAKE CITY, Nov. 10, 2016 -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, will demonstrate its molecular diagnostics platform at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina, November 10-12. At booth 302, the Company will show conference attendees the ease-of-use and simple workflow of its sample-to-result system, designed to help small to medium-sized hospitals reduce costs and provide better patient outcomes.
In addition to the exhibition, Great Basin Scientific’s technology will be presented with clinical study findings in a poster titled “Implementation of the Great Basin Group B Streptococcus (GBS) Assay using Hardy Carrot Broth in a Community Hospital Laboratory,” selected to be presented within the Infectious Diseases category. The study findings demonstrate the feasibility of carrot broth testing on the Great Basin system, a sample type not included in Great Basin’s GBS clinical trial. The demonstrated feasibility of carrot broth as a specimen culture media potentially expands the utility and market opportunity of the Company’s GBS test at hospitals and labs using carrot broth enrichment for patient samples.
The presenting author will be available during the poster session in the Exhibit Hall on Friday, November 11, 2:30pm – 3:30pm ET. Further, the poster will be available for download from the Great Basin website after the close of the Annual Meeting.
About AMP
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members practice in the various disciplines of molecular diagnostics, including infectious diseases, inherited conditions and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit www.amp.org and follow us on Twitter at @AMPath.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to, presentation at the AMP, the demonstrated feasibility of carrot broth as a specimen culture media potentially expands the utility and market opportunity for the Company’s GBS test and expansion of the Company’s menu. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on From 10-Q for the quarter ended June 30, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Media Contact: Nirav Suchak ICR 646.277.1257 [email protected] Investor Relations Contact: Betsy Hartman Great Basin Scientific 385.215.3372 [email protected]
